Gain Therapeutics

GANX

Market cap $61.1M

Overview Fund Activity

1.70 USD

+0.12

7.59%

At close Updated Sep 18, 1:26 PM EDT

1 day

7.59%

5 days

-1.73%

1 month

-3.95%

3 months

-5.03%

6 months

-28.57%

Year to date

-26.72%

1 year

14.86%

5 years

-84.82%

10 years

-84.82%

About: Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Employees: 25

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

120% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 5

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

44% more capital invested

Capital invested by funds: $8.24M [Q1] → $11.9M (+$3.61M) [Q2]

6% more funds holding

Funds holding: 33 [Q1] → 35 (+2) [Q2]

2.54% more ownership

Funds ownership: 10.11% [Q1] → 12.65% (+2.54%) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$6

253% upside

Avg. target

$7.67

351% upside

High target

$9

429% upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

BTIG Thomas Shrader	$9	Buy Reiterated	8 Sep 2025
Roth Capital Boobalan Pachaiyappan	$6	Buy Maintained	13 Aug 2025
HC Wainwright & Co. Raghuram Selvaraju	$8	Buy Reiterated	3 Jul 2025

See Analyst Rankings

Financial journalist opinion

Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease

Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after completing the first 90-day dosing schedule

Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease

Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

Ongoing Phase 1b trial of GT-02287 to be extended by an additional nine months for participants who enrolled in the original three-month study design The independent data monitoring committee (DMC) met recently and recommended to continue the study with no changes to study design BETHESDA, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the Company has received approval from the Bellberry Human Research Ethics Committee and Alfred Hospital Ethics Committee to extend dosing by an additional nine months in its ongoing Phase 1b clinical study of GT-022887, beyond the 90-day period currently allowed in protocol.

Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

Reached full enrolment of Phase 1b study evaluating GT-02287 in Parkinson's Disease (PD) with or without GBA1 mutations during 2Q 2025, earlier than anticipated Analysis of functional changes and biomarker activity at 90 days will be available during 4Q 2025 In July 2025 following the close of 2Q 2025, Gain completed an underwritten public offering that resulted in approximately $7.1 million of net proceeds BETHESDA, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended June 30, 2025, and provided a corporate update.

Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

BETHESDA, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next-generation of allosteric small molecule therapies, today announced that the Company's management team will participate in a fireside chat and one-on-one meetings at BTIG's Annual Virtual Biotechnology Conference, being held Tuesday, July 29th through Wednesday, July 30th.

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

BETHESDA, Md., July 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the pricing of an underwritten public offering of 4,501,640 shares of its common stock and warrants to purchase up to an aggregate of 2,250,820 shares of its common stock. The public offering price for each set of two shares of common stock and accompanying warrant to purchase one share of common stock is $3.11 per set of securities, yielding an effective price of $1.55 per share and $0.01 per warrant. The warrants are being sold at the rate of one warrant for every two shares of common stock. The warrants will have an exercise price of $1.65 per share, are exercisable immediately upon issuance and will expire five years following the date of issuance.

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

Gain Therapeutics Announces Proposed Public Offering

BETHESDA, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase common stock in an underwritten public offering. Gain expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and/or the warrants offered in the offering. All of the securities are being offered by the Company.

Gain Therapeutics Announces Proposed Public Offering

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation

As of June 30 th , 16 participants have enrolled in the Phase 1b, ahead of the original goal of at least 15 total participants by 3Q 2025

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation

Gain Therapeutics to Participate in Upcoming Investor Conferences

BETHESDA, Md., June 10, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present at two upcoming investor conferences: H.C.

Gain Therapeutics to Participate in Upcoming Investor Conferences

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

BETHESDA, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral presentation at the GBA1 Meeting 2025, being held June 5th-7th in Montreal, Canada.

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

First Biomarker Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected Mid-2025 First Biomarker Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected Mid-2025

Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

See News Rankings

Charts implemented using Lightweight Charts™